Next report date
Report period
H1 2024
EPS estimate
—
Revenue estimate
—
−0.3625USD
−9.32 MUSD
112.58 KUSD
38.92 M
About CELYAD ONCOLOGY
Sector
Industry
CEO
Michel E. Lussier
Website
Headquarters
Mont-Saint-Guibert
Employees (FY)
17
Founded
2007
ISIN
BE0974260896
FIGI
BBG00BNY0WS4
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of CLYYF is 0.3580 USD — it has decreased by 10.20% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Celyad Oncology SA stocks are traded under the ticker CLYYF.
Celyad Oncology SA is going to release the next earnings report on Sep 20, 2024. Keep track of upcoming events with our Earnings Calendar.
CLYYF stock is 11.35% volatile and has beta coefficient of 1.29. Check out the list of the most volatile stocks — is Celyad Oncology SA there?
CLYYF earnings for the last quarter are −0.19 USD per share, whereas the estimation was −0.87 USD resulting in a 78.75% surprise. The estimated earnings for the next quarter are −0.86 USD per share. See more details about Celyad Oncology SA earnings.
Yes, you can track Celyad Oncology SA financials in yearly and quarterly reports right on TradingView.
CLYYF net income for the last quarter is −5.20 M USD, while the quarter before that showed −4.08 M USD of net income which accounts for −27.38% change. Track more Celyad Oncology SA financial stats to get the full picture.
Today Celyad Oncology SA has the market capitalization of 14.00 M, it has decreased by 1.26% over the last week.
No, CLYYF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CLYYF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Celyad Oncology SA stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 17.00 employees. See our rating of the largest employees — is Celyad Oncology SA on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Celyad Oncology SA technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Celyad Oncology SA stock shows the sell signal. See more of Celyad Oncology SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Celyad Oncology SA EBITDA is −10.84 M USD, and current EBITDA margin is −9.61 K%. See more stats in Celyad Oncology SA financial statements.